Acadia Pharmaceuticals Projects $14 Billion Revenue with New R&D Leadership and Promising Pipeline

Acadia’s R&D Day and Upgradation

New Products and Strong R&D

Acadia Pharmaceuticals, in its 32 years of business and has currently organized its first R&D day, predicting annual sales of around $12 billion from its investigational chain. Daybue for Rett syndrome and Nuplazid for parkinson’s disease psychosis are available products in the market. Along with the products, seven experimental assets in preclinical and clinical studies are in alignment. Acadia sees the potential $14 billion in annual revenue, including the two products and studies in the market. The new leader, Elizabeth (Liz) Thompson, is now a part of the company, designated as the head of research and development, before Owen Adams.

Owen Adams demonstrates Acadia as a rare and neurological diseases company, the one who is mainly focuses on systematic and symptomatic treatments for neurodegenerative diseases. The two assets are included, in the middle or near the end of the studies for hyperphagia in Prader-Willi syndrome, Lewy body dementia, and Alzheimer's disease with psychosis. The company is rising in terms of trends, including AbbVie, Neumora, and Bristol Myers Squibb Therapeutics, which provides a full treatment of Alzheimer's disease.

The Acadia nuplazid (pimavanserin) was the first FDA-approved treatment for delusions and hallucinations linked with Parkinson’s disease psychosis in 2016. The ACP-204 is under phase 2 trials for Lewy body dementia and alzheimer’s disease psychosis.

Views and Statements

Owen Adams' overall efforts, expertise, and excitement have helped the company in their growth. Together, Elizabeth Thompson and Catherine Owen Adams, the R&D duo, have led the Acadia company since last summer. Owen Adam says, “Though for now we are a small biotech, we believe and see potential in us to be a biotech powerhouse. The primary priority was always to stabilize the commercial business that we have achieved now. The secondary priority was to redefine the company’s strategy for the future. Previously, it was a bit disturbing to showcase much of the pipeline, but Liz and I challenged that and came forward showing additional exciting opportunities and also new thoughts about partnership and sharpening the focus.” Further, “whilst memory loss is a very severe psychosis and agitation which disturbs families and at home care treatment becomes difficult. The reason for long-term care facilities is not memory loss but agitation or psychosis. So, there’s more to focus on.”

Improvement in pimavanserin’s profile is what Owen Adam is most excited about due to some personal reasons, because her parents are infected with one of these two diseases. She understands the disturbance and destruction faced by the families.